SG10201811729PA - Membrane-penetrating peptides to enhance transfection and compositions and methods for using same - Google Patents

Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Info

Publication number
SG10201811729PA
SG10201811729PA SG10201811729PA SG10201811729PA SG10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA
Authority
SG
Singapore
Prior art keywords
cargo
membrane
compositions
methods
peptides
Prior art date
Application number
SG10201811729PA
Other languages
English (en)
Inventor
Mollerat Du Jeu Xavier De
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Publication of SG10201811729PA publication Critical patent/SG10201811729PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG10201811729PA 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same SG10201811729PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361915429P 2013-12-12 2013-12-12

Publications (1)

Publication Number Publication Date
SG10201811729PA true SG10201811729PA (en) 2019-02-27

Family

ID=52273587

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201604697TA SG11201604697TA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
SG10201811729PA SG10201811729PA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201604697TA SG11201604697TA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Country Status (11)

Country Link
US (3) US9856496B2 (zh)
EP (2) EP3756690A3 (zh)
JP (2) JP6912887B2 (zh)
KR (1) KR102532559B1 (zh)
CN (2) CN113105559A (zh)
AU (2) AU2014361806B2 (zh)
BR (1) BR112016013516A8 (zh)
CA (1) CA2933561A1 (zh)
ES (1) ES2808866T3 (zh)
SG (2) SG11201604697TA (zh)
WO (1) WO2015089487A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013166339A1 (en) * 2012-05-02 2013-11-07 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
EP2862084A4 (en) 2012-06-15 2016-11-30 Soft Machines Inc METHOD AND SYSTEM FOR IMPLEMENTING RECOVERY FROM A SPECULATIVE TRANSMISSION OF FAULT FORECASTS / ERRORS DUE TO THE CHANGE AND OPTIMIZATION OF MEMORY LOADS
KR101826080B1 (ko) 2012-06-15 2018-02-06 인텔 코포레이션 통합된 구조를 갖는 동적 디스패치 윈도우를 가지는 가상 load store 큐
WO2013188696A2 (en) 2012-06-15 2013-12-19 Soft Machines, Inc. An instruction definition to implement load store reordering and optimization
KR101818967B1 (ko) 2012-06-15 2018-01-16 인텔 코포레이션 명확화 없는 비순차 load store 큐
WO2013188460A2 (en) 2012-06-15 2013-12-19 Soft Machines, Inc. A virtual load store queue having a dynamic dispatch window with a distributed structure
EP2862068B1 (en) 2012-06-15 2022-07-06 Intel Corporation Reordered speculative instruction sequences with a disambiguation-free out of order load store queue
CA2933561A1 (en) 2013-12-12 2015-06-18 Life Technologies Corporation Membrane-penetrating peptides to enhanced transfection and compositions and methods for using same
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2017011598A1 (en) 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells
JP2019528284A (ja) 2016-08-17 2019-10-10 ファクター バイオサイエンス インコーポレイテッド 核酸産物およびその投与方法
EP3519566A1 (en) * 2016-09-30 2019-08-07 Life Technologies Corporation Serum-free suspension system for lentiviral production
US11782050B2 (en) 2017-09-19 2023-10-10 Cannametrix, Llc Cell-based assay for quantifying the potency and efficacy of cannabinoids and/or terpenoids, and methods of use thereof
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
CN113454101A (zh) * 2019-02-22 2021-09-28 生命技术公司 用于腺相关病毒产生的悬浮系统
CN113874029A (zh) * 2019-04-01 2021-12-31 汉阳大学校产学协力团 基于cp2c靶向肽的抗癌剂
KR102261371B1 (ko) * 2019-04-01 2021-06-08 한양대학교 산학협력단 CP2c 표적 펩티드 기반 항암제
EP4010027A1 (en) * 2019-08-05 2022-06-15 PolyPlus Transfection Compositions for transfecting a nucleic acid molecule into a cell comprising heterocyclic compounds grafted to a cationic polymer, and their applications
KR102515464B1 (ko) * 2020-04-29 2023-03-28 연세대학교 원주산학협력단 핵산 또는 유전자 형질감염 효율을 개선하는 세포독성 완화 막 투과 펩타이드 및 이의 용도
AU2022306542A1 (en) 2021-07-08 2024-01-18 Nippon Shinyaku Co., Ltd. Precipitation suppressing agent
TW202308664A (zh) 2021-07-08 2023-03-01 日商日本新藥股份有限公司 腎毒性減輕劑
WO2023282345A1 (ja) 2021-07-08 2023-01-12 日本新薬株式会社 腎毒性軽減剤
CN113563429A (zh) * 2021-07-19 2021-10-29 天津大学 一种基于烷基化多肽的核酸递送系统及制备方法与应用
WO2023014909A1 (en) * 2021-08-04 2023-02-09 AJK Biopharmaceutical, LLC Amphiphilic peptides for nucleic acid and protein delivery
CN114106095B (zh) * 2021-11-11 2023-06-09 华南理工大学 基于聚集诱导发光原理的细胞自噬检测分子探针及其制备方法和应用
WO2024006937A1 (en) 2022-06-30 2024-01-04 Life Technologies Corporation Lipid compositions for in vivo delivery
GB202211597D0 (en) 2022-08-09 2022-09-21 Nchain Licensing Ag Computer-implemented method and system
CN115947817A (zh) * 2023-02-22 2023-04-11 广州庆毅生物医药科技有限公司 一种肿瘤相关多肽及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5316948A (en) 1992-09-04 1994-05-31 Life Technologies, Inc. N4 -methyl-2'-deoxycytidine 5'-triphosphate and its use in polymerase-catalyzed nucleic acid syntheses
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
AU5979296A (en) 1995-06-07 1996-12-30 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
US7166745B1 (en) 1998-11-12 2007-01-23 Invitrogen Corporation Transfection reagents
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
CA2797652C (en) 2000-07-21 2016-03-08 Revance Therapeutics, Inc. Multi-component biological transport systems
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
GB0106315D0 (en) * 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
WO2004063342A2 (en) 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
EP1628647A4 (en) 2003-05-22 2007-10-24 Molecular Transfer Inc LIPIDS FOR THE TRANSFECTION OF NUCLEIC ACIDS
JP4755591B2 (ja) * 2003-08-14 2011-08-24 ディアトス （ソシエテ アノニム） 対象物質の細胞および／または細胞核中への侵入を促進するアミノ酸配列
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
JP2009519033A (ja) 2005-12-16 2009-05-14 ディアト 核酸を細胞に送達するための細胞貫通ペプチド結合体
DE602006020617D1 (de) 2005-12-30 2011-04-21 Evonik Roehm Gmbh Lactoferrin-peptide, geeignet als in die zelle eindringende peptide
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
NZ572564A (en) 2006-05-05 2011-10-28 Molecular Transfer Inc Novel reagents for transfection of eukaryotic cells
WO2008108505A1 (ja) 2007-03-07 2008-09-12 Japan As Represented By President Of International Medical Center Of Japan 新規核内移行ペプチド
EP2641911A3 (en) * 2008-12-23 2014-01-01 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
US20110053829A1 (en) * 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011127210A1 (en) 2010-04-06 2011-10-13 Massachusetts Institute Of Technology Targeted delivery of nucleic acids
CN103097397B (zh) * 2010-05-30 2015-11-25 多伦多大学管理委员会 作为抗癌化合物载体的线粒体穿透肽
JP5726299B2 (ja) 2010-06-14 2015-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 細胞透過性ペプチドおよびその使用
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CN108358812B (zh) 2010-11-15 2021-05-11 生命技术公司 含胺的转染试剂及其制备和使用方法
CN102153629B (zh) * 2011-01-20 2013-07-24 华中科技大学 一种短肽及其应用
US8853145B2 (en) * 2011-11-14 2014-10-07 Carlos Witte-Hoffmann BLID; a novel protein domain for interaction with the Bcl-2 family of proteins
JP2015512246A (ja) * 2012-03-15 2015-04-27 パーミオン バイオロジクス， インコーポレイテッド 細胞内抗体および抗体様モイエティの送達のための細胞透過組成物ならびに使用方法
CA2933561A1 (en) 2013-12-12 2015-06-18 Life Technologies Corporation Membrane-penetrating peptides to enhanced transfection and compositions and methods for using same
KR102476764B1 (ko) * 2015-12-23 2022-12-14 에스케이하이닉스 주식회사 소자분리구조 및 그 제조 방법
US9926825B2 (en) 2016-04-19 2018-03-27 GM Global Technology Operations LLC Method and apparatus for exhaust purification for an internal combustion engine

Also Published As

Publication number Publication date
BR112016013516A2 (zh) 2017-08-08
AU2020202002B2 (en) 2021-08-05
US20200392537A1 (en) 2020-12-17
ES2808866T3 (es) 2021-03-02
US9856496B2 (en) 2018-01-02
CN113105559A (zh) 2021-07-13
EP3079723A1 (en) 2016-10-19
JP6912887B2 (ja) 2021-08-04
EP3756690A2 (en) 2020-12-30
US20150211021A1 (en) 2015-07-30
JP2017500856A (ja) 2017-01-12
KR102532559B1 (ko) 2023-05-16
WO2015089487A1 (en) 2015-06-18
US10760098B2 (en) 2020-09-01
CA2933561A1 (en) 2015-06-18
AU2014361806B2 (en) 2019-12-19
KR20160103024A (ko) 2016-08-31
US20180163231A1 (en) 2018-06-14
EP3756690A3 (en) 2021-03-17
JP2020015747A (ja) 2020-01-30
JP6985347B2 (ja) 2021-12-22
CN106456793B (zh) 2021-04-30
BR112016013516A8 (pt) 2020-05-19
SG11201604697TA (en) 2016-07-28
AU2020202002A1 (en) 2020-04-09
CN106456793A (zh) 2017-02-22
AU2014361806A1 (en) 2016-07-28
EP3079723B1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
SG10201811729PA (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
Zuris et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
MX2020006065A (es) Metodos y productos para la produccion y administracion de acido nucleico.
EA201790968A1 (ru) Опосредуемая пептидом доставка направляемой рнк эндонуклеазы в клетки
WO2010129023A3 (en) Supercharged proteins for cell penetration
BR112013024220B8 (pt) Métodos de introdução de um ácido nucleico de interesse em uma célula vegetal com parede celular, de expressão estável de um gene e de transferência de um gene para uma célula vegetal
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
Zuris et al. Efficient delivery of genome-editing proteins in vitro and in vivo
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2007130073A3 (en) Novel reagents for transfection of eukaryotic cells
WO2010115052A3 (en) Induced pluripotent stem cells
IL192131A0 (en) Peptides useful as cell-penetrating peptides
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
AU2012300633A8 (en) Cell- penetrating peptides having a central hydrophobic domain
MX2010005451A (es) Sistema para la liberacion en una celula positiva para xcr1 y usos de este.
RU2014110901A (ru) Пептидные частицы и их применение
IN2014CN04734A (zh)
RU2013116447A (ru) Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина
WO2014070687A3 (en) Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells
WO2013134129A3 (en) Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins
WO2023018990A3 (en) Lipids for nucleic acid delivery
IN2014DN09963A (zh)
EP2594638B1 (en) Method for introducing nucleic acid to cell and nucleic acid complex